Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms
Emma I Kopra, Jason Ferris, Adam Winstock, Allan H. Young, James Rucker
Journal of Psychopharmacology April 7, 2022 DOI: 10.1177/02698811221084063 via OpenAlex
Summary
AI-generated from the abstractAmong 9,233 people who used magic mushrooms in the past year, only 19 (0.2%) sought emergency medical treatment, corresponding to a per-event risk of 0.06%. Younger age was the only factor linked to a higher chance of needing emergency care. The most common symptoms were psychological—anxiety, panic, paranoia, and suspiciousness. Poor mindset, poor setting, and mixing substances were the most frequently cited reasons for the incidents. All but one person returned to normal within 24 hours. The findings confirm that psilocybin mushrooms are relatively safe, with serious adverse reactions being rare and short-lived.
Study at a glance
| Characteristics | Cross-sectional survey Peer reviewed |
|---|---|
| Sample size | 9,233 |
| Population | Past year magic mushroom users who completed the 2017 Global Drug Survey |
| Duration | 12-month prevalence |
| Keywords | Adverse effect Magic telescope Psychology Medicine Medical emergency |
| Citations | 65 |
| Key finding | Only 0.2% of past year magic mushroom users sought emergency medical treatment, and all but one recovered within 24 hours. |
Abstract
Background: Psilocybin-containing mushrooms are used for recreational, spiritual, self-development and therapeutic purposes. However, physiologically relatively nontoxic, adverse reactions are occasionally reported. Aims: This study investigated the 12-month prevalence and nature of magic mushroom-related adverse reactions resulting in emergency medical treatment seeking in a global sample of people reporting magic mushroom use. Methods: We use data from the 2017 Global Drug Survey – a large anonymous online survey on patterns of drug use conducted between November 2016 and January 2017. Results: Out of 9233 past year magic mushroom users, 19 (0.2%) reported having sought emergency medical treatment, with a per-event risk estimate of 0.06%. Young age was the only predictor associated with higher risk of emergency medical presentations. The most common symptoms were psychological, namely anxiety/panic and paranoia/suspiciousness. Poor ‘mindset’, poor ‘setting’ and mixing substances were most reported reasons for incidents. All but one respondent returned back to normality within 24 h. Conclusions: The results confirm psilocybin mushrooms are a relatively safe drug, with serious incidents rare and short lasting. Providing harm-reduction information likely plays a key role in preventing adverse effects. More research is needed to examine the detailed circumstances and predictors of adverse reactions including rarer physiological reactions.